Signal transducer and activator of transcription (STAT) 3 regulates many cardinal features of cancer including cancer cell growth, apoptosis resistance, DNA damage response, metastasis, immune escape, tumor angiogenesis, the Warburg effect and oncogene addiction and has been validated as a drug target for cancer therapy. Several strategies have been used to identify agents that target Stat3 in breast cancer but none has yet entered into clinical use. We used a high-throughput fluorescence microscopy search strategy to identify compounds in a drug-repositioning library (Prestwick library) that block ligand-induced nuclear translocation of Stat3 and identified piperlongumine (PL), a natural product isolated from the fruit of the pepper Piper longum. PL inhibited Stat3 nuclear translocation, inhibited ligand-induced and constitutive Stat3 phosphorylation, and modulated expression of multiple Stat3-regulated genes. Surface plasmon resonance assay revealed that PL directly inhibited binding of Stat3 to its phosphotyrosyl peptide ligand. Phosphoprotein antibody array analysis revealed that PL does not modulate kinases known to activate Stat3 such as Janus kinases, Src kinase family members or receptor tyrosine kinases. PL inhibited anchorage-independent and anchorage-dependent growth of multiple breast cancer cell lines having increased pStat3 or total Stat3, and induced apoptosis. PL also inhibited mammosphere formation by tumor cells from patient-derived xenografts. PL's antitumorigenic function was causally linked to its Stat3-inhibitory effect. PL was non-toxic in mice up to a dose of 30 mg/kg/day for 14 days and caused regression of breast cancer cell line xenografts in nude mice. Thus, PL represents a promising new agent for rapid entry into the clinic for use in treating breast cancer, as well as other cancers in which Stat3 has a role.
INTRODUCTION
Signal transducer and activator of transcription 3 (Stat3) is a member of a family of seven closely related proteins responsible for transmission of peptide hormone signals from the extracellular surface of cells to the nucleus. 1 Stat3 was subsequently demonstrated to be a master regulator of several key hallmarks and enablers of cancer cells [2] [3] [4] [5] including cell proliferation, 6 resistance to apoptosis, 7 metastasis, 2 immune evasion, 8 tumor angiogenesis, 9 epithelial-mesenchymal transition, 10 response to DNA damage 11 and the Warburg effect. 12 In addition, Stat3 is a key mediator of oncogene addiction in several types of tumors. 13 In breast cancer, Stat3 activity is increased in the self-renewing CD44 + CD24 À tumor-initiating cell (TIC) population where it contributes to cancer initiation, maintenance and relapse. [14] [15] [16] Thus, Stat3 is an attractive target for anticancer drug development, including treatment for breast cancer.
Peptide hormone binding to growth factor or cytokine receptors 17, 18 causes receptor oligomerization and activation of intrinsic or receptor-associated tyrosine kinases, respectively. These activated kinases phosphorylate receptor tyrosine residues creating docking sites for recruitment of cytoplasmic Stat3. 17, 18 Stat3 docks to receptor phosphotyrosyl (pY) peptide sites through its Src-homology (SH) 2 domain, which leads to its phosphorylation on Y 705 followed by Stat3 tail-to-tail homodimerization (SH2 domain of each monomer binds the pY 705 peptide domain of its partner). Stat3 homodimers accumulate in the nucleus, where they bind to specific Stat3 response elements in the promoter of target genes and regulate their transcription.
Stat3 activity is increased in~50% of all cancers. 19 Although increased Stat3 activity in human cancers can result from naturally occurring Stat3 mutations, for example, human inflammatory hepatocellular adenomas and large granular lymphocytic leukemia, 20, 21 it more commonly results from activation of upstream receptor tyrosine kinases, for example, epidermal growth factor receptor, or tyrosine kinase-associated receptors, for example, the family of interleukin-6 (IL-6)-type (IL-6) cytokine receptors, or G protein-coupled receptors. 17, 18, 22, 23 In addition, members of the Src kinase family, such as Src, Lck, Hck, Lyn, Fyn or Fgr, can activate Stat3 either directly or downstream of an receptor tyrosine kinase or G protein-coupled receptor. 22, 23 Several small molecule drug development programs have emerged directed at identifying drug-like compounds that target 1 Stat3. These programs have targeted either the Stat3 homodimer or the Stat3 SH2 domain. [24] [25] [26] [27] Although these programs have identified drug-like candidates that show activity in cell-based assays and pre-clinical cancer models, none has yet entered into clinical use.
In an effort to fill this clinical need, we used a single-cell, highthroughput fluorescent cell-based assay to screen the Prestwick drug-repositioning chemical library for compounds with ability to block nuclear accumulation of ligand-activated green fluorescent protein (GFP)-Stat3. This screen identified piperlongumine (PL), an alkyl amide, and an active component of the long pepper (Piper longum) fruit, used for centuries in Ayurvedic medicine to treat a variety of illnesses including stomach ulcers, tumors and circulatory problems. PL inhibited Stat3 cytoplasmic-to-nuclear translocation and ligand-mediated activation of Stat3 phosphorylation and reduced constitutive Stat3 phosphorylation in breast cancer cell lines, mediating its effect by inhibiting Stat3 binding to its pY-peptide ligand. PL reduced levels of Stat3 target genes in breast cancer cells, inhibited anchorage-dependent and -independent growth of breast cancer cells, inhibited mammosphere (MS) formation by patient-derived human breast cancer xenografts that expressed moderate-to-high levels of constitutively activated Stat3 and inhibited growth of breast cancer line xenograft tumors in nude mice. Thus, PL represents a promising new agent for potential hit-to-lead development and rapid entry into the clinic for use in treating breast cancer, as well as other cancers in which Stat3 has a role.
RESULTS
High-throughput fluorescence microscopy (HTFM) screening of the Prestwick chemical library identified PL as a potent inhibitor of ligand-stimulated Stat3 nuclear translocation Screening of the Prestwick chemical library identified six compounds that inhibited Stat3α nuclear translocation. Out of these, three were cytotoxic drugs used in chemotherapy; the other three were chrysene 1,4 quinone (IC 50 = 10 μM), merbromin (IC 50 = 10 μM) and PL (IC 50 = 1.7 μM; Figures 1a and c and Table 1 ). Chrysene is a weakly carcinogenic polycyclic aromatic hydrocarbon. 28 Merbromin/mercurochrome is an organomercuric disodium salt. PL is an alkyl amide isolated from the long pepper (Piper longum) fruit, which has been used for centuries in Ayurvedic medicine to treat a variety of illnesses including stomach ulcers, tumors and circulatory problems.
Two isoforms of Stat3 (α/p92 and β/p83), resulting from alternative splicing, are present within cells at a 4:1 ratio. 29 We previously demonstrated that both isoforms exhibited similar dynamics of nuclear accumulation in mouse embryonic fibroblast (MEF) cells following stimulation with IL-6/sIL6Rα. 30 To determine if PL inhibited nuclear translocation of Stat3β in addition to Stat3α, we used stably expressing MEF/GFP-Stat3β in HTFM assay. PL blocked ligand-induced nuclear translocation of GFP-Stat3β cells with an IC 50 similar to that in GFP-Stat3α cells (IC 50 = 0.9 ± 0.6 μM; Figures 1b and c; Table 1 ).
PL inhibits ligand-stimulated phosphorylation of Stat3 in the myeloid leukemia cell line, Kasumi-1, and in breast cancer cell lines, and rapidly decreases constitutive phosphorylation of Stat3 in breast cancer cell lines through inhibition of Stat3 binding to its pY-peptide ligand Nuclear accumulation of Stat3 is facilitated by its phosphorylation on Y 705 . To assess if PL inhibited ligand-mediated Stat3 phosphorylation, we examined the ability of PL to inhibit granulocyte colony-stimulating factor (G-CSF)-induced Stat3 phosphorylation of the myeloid leukemia cell line, Kasumi-1, by phosphoflow. PL potently inhibited G-CSF-induced Stat3 phosphorylation (IC 50 = 3.7 ± 1.7 μM; Figure 2 and Table 1 ).
Stat3 is constitutively phosphorylated in multiple cancers, including breast cancer. 2 We examined levels of pStat3 in a panel of breast cell lines (Figure 3a) . The non-tumorigenic epithelial breast cell lines (MCF-10A and MCF-12A) and six breast cancer cell  lines (MCF-7, T47D, ZR-75-1, BT-474, MDA-MB 453 and SK-BR-3) had low levels of pStat3, whereas five cell lines (Hs578T, HCC1954, MDA-MB-231, MDA-MB-468 and Sum159PT) had high pStat3 levels. PL treatment of two of the breast cancer cell lines with high constitutive levels of pStat3, MDA-MB-231 and MDA-MB-468, for 1.5 h reduced pStat3 levels in each by >70% (Figures 3c and d and  Table 1 ; IC 50 = 0.4-2.8 μM) without substantially affecting levels of total Stat3 or pStat1, pStat5 and total Stat1 (Figure 3e) . To determine the kinetics of reduction of constitutive pStat3 by PL, we treated MDA-MB-468 cells with PL (30 μM) for 15 min-24 h and determined pStat3, total Stat3 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Figure 3f ). Levels of pStat3 were reduced by >50% as early as 15 min and maximally reduced by 30 min.
We also tested PL's effect on Stat3 phosphorylation induced by IL-6 plus sIL6Rα in three pStat3-low breast cancer cell lines MCF-7, MDA-MB-453 and T47D (Figure 3g ). IL-6/sIL6Rα treatment (at 150 ng/ml for 20 min) increased the pStat3 levels by 6.8-, 14.9-and 26.6-fold in MCF-7, MDA-MB-453 and T47D cells, respectively (data not shown). PL pre-treatment for 2 h completely blocked the ability of IL-6/sIL6R to stimulate Stat3 phosphorylation in MCF-7 (IC50 = 0.9 μM; Figure 3g and Table 1 ), MDA-MB-453 (IC50 = 0.9 μM; Figure 3g and Table 1 ) and T47D cells (IC50 = 2.7 μM; Figure 3g and Table 1 ).
To determine the mechanism by which PL inhibits ligandinduced and constitutive phosphorylation of Stat3, we tested PL for its ability to inhibit Stat3 binding to its phosphopeptide ligand in a surface plasmon resonance-based binding assay. 27 PL potently inhibited Stat3 binding to its pY-peptide ligand with an IC 50 = 1.5 μM (Figure 4 , Table 1 ) which, using the Cheng-Prussoff equation, converts to a K i of 68 nM.
PL alters expression of multiple Stat3-regulated genes important for oncogenesis To assess if the effects of PL on Stat3 extend to modulation of Stat3-regulated genes, we examined mRNA levels of 51 known Stat3-regulated gene targets (Supplementary Tables 2 and 3) by real-time PCR in MDA-MB-468 cells treated with PL (30 μM, 6-8 h). PL significantly downregulated genes encoding cell cycle and apoptosis resistance proteins, mitochondrial proteins, and oxidative stress defense proteins (Supplementary Tables 2 and 3 ). Out of the 46 genes that had detectable mRNA (threshold cycle o 30), 21 (46%) genes had significantly altered expression (6 h) groups. Notably, PL affected 6/9 (67%), apoptosis-related genes, including the anti-apoptotic genes Bcl-2, BcL-xL, Survivin, XIAP and CIAP. Treatment for 8 h increased the number of Stat3 gene targets affected by PL to 28/46 (61%) and increased the degree of PLinduced changes (Bcl-2 from 15 to 20%; Survivin/XIAP from 30 to 40%; CIAP/BcL-xL from 50-60 to 70%). Conversely, PUMA, a proapoptotic, BH3-only member of the Bcl-2 family shown to be upregulated by p53, was highly upregulated by PL both at 6 h (~4-fold, P o 0.005, Supplementary Table 2) as well as 8 h (~5-fold, Po 0.01); this result may have been anticipated as previous reports showed that Stat3 antagonizes the transcriptional activities of p53. 31 Thus, the inhibitory effect of PL on Stat3 phosphorylation and nuclear translocation was accompanied by marked modulation in Stat3-regulated gene expression in breast cancer cells.
PL inhibits anchorage-independent and anchorage-dependent growth of breast cancer cell lines and results in cell apoptosis Previous reports indicated that breast cancer cell lines (MDA-MB-231, MDA-MB-468 and Hs578) depend on Stat3 for growth and/or survival. 15, 32 To determine the effect of PL on their growth, cells were incubated without or with PL for 24-48 h and assessed for anchorage-independent and anchorage-dependent growth ( Figure 5 ). The ability of epithelial cancer cells to grow under anchorage-independent conditions (that is, in ultra-low attachment plates) is indicative of multiple tumorigenic properties, for example, survival, growth, anoikis resistance and hence closely approximates their tumor-forming ability. 33 PL potently inhibited both anchorage-independent (Figures 5a and b Figure 5d ). Caspase-3 cleavage was first noted at 12 h, increasing 12-fold compared with earlier time points, indicating that PL induces breast cancer cells to undergo apoptosis in a timedependent manner.
PL blocks MS-forming capacity of breast cancer cells isolated from patient-derived human breast cancer xenografts Previous reports demonstrated that Stat3 was activated within a sub-population of breast cancer cells that have tumor-initiating characteristics, so called TICs, 15 including TIC described within breast cancer patient-derived xenografts (PDXs) established from biopsies of patients and passaged in severe combined immunodeficient (SCID)/Beige mice. 16, 34, 35 To examine the effect of PL on breast cancer PDX, we first determined pStat3 levels in 28 of them (Table 1 ) using four-parameter logistic model/dose response using GraphPad.
( Figure 6a ). Levels of pStat3 in most PDX were higher than in T47D and MCF-7 tumor xenografts, which were generated in SCID/Beige mice from pStat3-low breast cancer cell lines. We examined whether PL inhibited the ability of single-cell suspensions of two of these PDX, MC1 36 and BCM-2665, to form MSs, a well-described feature of TIC. 15 The ability of PL to inhibit Stat3 is linked to its ability to inhibit breast cancer cell growth To examine the link between the specific anti-Stat3 activity of PL and its breast cancer cell growth inhibitory capabilities, we used two different model systems that demonstrate increased cancer cell functions as a direct consequence of increased Stat3 activity or expression. In the first one, we used a lentiviral reporter system (Wei et al., in revision) for detecting cells with high Stat3 activity. This system included the Stat3-GFP reporter (GFP under the control of four repeats of the M67 sequences, a high-affinity variant of the Stat3-binding sequence from human c-fos promoter). The breast cancer cell line, SUM159PT, was positive for reporter activity (reporter positivity defined by higher GFP intensity in Stat3-GFP-transduced cells compared with TATA-GFPtransduced cells), which matched with our findings regarding its pStat3 status (Figure 3a ). SUM159PT cells transduced with the Stat3-GFP reporter were injected into pre-cleared mouse mammary gland of immunocompromised SCID/Beige mouse. growth directly supports the conclusion that PL suppressed Stat3-mediated oncogenic properties of these cells.
PL treatment inhibits the growth of human breast cancer cell line xenografts by reducing levels of both pStat3 and Stat3 upregulated gene transcripts within tumors To test the ability of PL to inhibit growth of human breast cancer tumors in mice, PL (15 mg/kg body weight per day) or dimethylsulphoxide (DMSO; vehicle) was administered for 3 weeks by intraperitoneal injection into nude mice bearing human breast cell line (MDA-MB-468) tumor xenografts starting when the average tumor size in each group was~100 mm 3 . Tumor measurements were taken thrice weekly. PL inhibited tumor growth (Figure 8a ) with the difference in tumor volume between PL-treated vs vehicle-treated mice becoming significant after only two doses and continuing until the end of treatment. The mice were killed 1 day after the last treatment; tumors were excised and weighed. PL treatment over 21 days reduced tumor weight by >50% (Figure 8b ; P o 0.05). Whole-protein extracts of tumor tissue from DMSO-treated mice (n = 12) and PL-treated mice (n = 11) were examined for pStat3, tStat3 and GAPDH levels using Luminex assays. Levels of pStat3 were reduced by 40% in tumors from PL-treated mice (0.09 ± 0.05) compared with tumors from vehicletreated mice (0.15 ± 0.04; P o0.01; Figure 8c ).
We demonstrated above that the inhibitory effect of PL on Stat3 phosphorylation and nuclear translocation in cell lines was accompanied by marked reductions in mRNA transcripts of known Stat3 upregulated genes within breast cancer cell lines in vitro, including BcL-xL, Survivin, XIAP, CIAP, MT2A, NFE2L1 and Glut1. To determine the effects of PL treatment on their levels within tumors, we measured mRNA transcript levels of these genes in tumors from PL-treated mice and vehicle-treated mice by quantitative reverse transcriptase-PCR. Transcript levels of each of these Stat3 upregulated gene targets were reduced by up to 53% in tumors from PL-treated mice (N = 10) vs tumors from vehicle-treated mice (N = 9; P o 0.001, Supplementary Table 4 ). In particular, PL treatment reduced the β-actin-normalized levels of BcL-xL by 52.5% and of Survivin by 45% compared with vehicletreated mice (P o0.05; Figure 8d ). Thus, PL prevented growth of a Stat3-dependent breast cancer cell line xenografts by reducing levels of pStat3 within the tumor and by down-modulating Stat3-regulated genes important for tumor growth.
DISCUSSION
-regulated genes. PL inhibited anchorage-independent and anchorage-dependent breast cancer cell growth and induced apoptosis of these cells. PL treatment prevented growth of breast cancer cell line xenografts in nude mice through effectively targeting Stat3 within these tumors resulting in reduced levels of Stat3-regulated, tumor survival genes. Thus, PL represents a promising new agent for hit-to-lead development and subsequent entry into the clinic for use in treating breast cancer, as well as other cancers in which Stat3 has a role.
Evidence that PL mediates breast cancer cell apoptosis through Stat3-dependent modulation of key anti-and pro-apoptotic molecules clearly emerges from our results. PL treatment of the Stat3-dependent breast cancer cell line, MD-MB-468, for 6-8 h decreased mRNA levels of five major anti-apoptotic proteins (Bcl-2, BcL-xL, Survivin, XIAP and CIAP) by 20 to 68% (Supplementary  Table 2 ), whereas increasing mRNA levels of PUMA, a proapoptotic Bcl-2 member, by fivefold, and FAS (CD95), the death domain containing receptor, by twofold. These mRNA changes at 6-8 h were followed at 12 h by activation of caspase-3 indicating induction of apoptosis. PL also inhibited growth of MDA-MB-468 xenografts in nude mice through efficient in vivo reduction of pStat3 levels accompanied by reduction in 8 of 8 Stat3-regulated, anti-apoptosis genes examined including BcL-xL and Survivin (each by~50%, P o 0.05). Although not specifically examined, it is likely that PL targets Stat3 in other cell types within tumors, such as tumor epithelial cells, stromal fibroblasts and endothelial cells, in addition to the breast cancer cells themselves. Tumor epithelial cells, stromal fibroblasts and endothelial cells have been reported to contribute to oncogenic transformation and maintenance, in part, through a Stat3-dependent mechanism, 39 thus, targeting Stat3 within them would be expected to augment the antitumor effects of PL.
A phosphoprotein antibody array analysis revealed that PL treatment (30 uM for 2 h) does not affect Stat3 activation indirectly through targeting other components of signaling pathway in breast cancer cell line MDA-MB-468. Using a >1.4-fold change (increase or decrease; P o0.01, t-test) and minimum basal level of expression >40 as cutoff for designating a measurable change (Supplementary Table 5 ), we found that PL does not change phosphorylation of receptor tyrosine kinases and non-receptor tyrosine kinases known to be involved in Stat3 phosphorylation including Abl, Brk, epidermal growth factor receptor, Her2, IGF1R, Lyn, Met and Src (implicated in Stat3 activation in breast cancer) and other known upstream kinases including Scr family kinases Lck, Hck and Fyn. Neither does it affect other known positive regulators of Stat3 in breast and other cancers and cell types; for example, integrin β3, integrin β4, ER-α and progesterone receptor. In addition, PL did not affect known inhibitors of Stat3 activation such as BTK, Gab1, SHP-1, SHP-2, GRB2 and WWOX (Supplementary Table 5 ). Thus, the mechanism of Stat3 inactivation by PL appears to be its ability to directly inhibit Stat3 binding to its pY-peptide ligand (Figure 4) .
Using the same criteria as above to designate what constitutes a measurable change in phosphorylation, the phospho-proteome screen also revealed that PL did not significantly affect levels of various components of other major pro-oncogenic signaling pathways, for example, activator Protein 1 (AP1), phosphatidylinositol 3 kinase/Akt/mammalian target of rapamycin, focal adhesion kinase (FAK) and mitogen-activated protein kinase (extracellular signal-regulated kinase, c-Jun N-terminal kinase and p38) pathway (Supplementary Table 6 ). There was, however, a significant decrease (by~30-40%) in the absolute levels of p65, a major subunit of the nuclear factor-κB protein complex (Supplementary Table 6 ). However, p65 (RelA) has two potential Stat3-binding sites in its promoter (data not shown) suggesting that the PL-mediated decrease in p65 may be mediated indirectly through its effect on Stat3.
Although we established that PL specifically targets breast cancer cell lines with increased pStat3 levels, PL was recently shown to inhibit the growth of two breast cancer cell lines with low levels of pStat3, BT-474 and MCF-7. 40 Recently, unphosphorylated (U)-Stat3, which represents the bulk of total Stat3, has been described to be oncogenic, 41, 42 in part, by modulating known pStat3 gene targets with pro-oncogenic effects including c-Myc, c-fos and Bcl-xL, as well as genes such as RANTES, cdc2, cyclin B1, IL-6, IL-8, Met and M-RAS through its cooperative binding with nuclear factor-κB to specific κB elements and/or other novel mechanisms. 41, 43, 44 These observations raised the possibility that PL was targeting not only pStat3 but U-Stat3 as well. To address this possibility, we measured levels of constitutive pStat3 levels (Figure 3a) as well as total Stat3, as a surrogate of U-Stat3 (Figure 3b ) in 11 breast cancer cell lines and two non-tumorigenic breast epithelial cell lines, MCF-10A and MCF-12A. The two normal breast cell lines, as well as six breast cancer cell lines (MCF-7, T47D, ZR-75-1, BT-474, MDA-MB-453 and SK-BR3) had low pStat3 levels, whereas five cell lines (Hs578T, HCC1954, MDA-MB-231, MDA-MB-468 and Sum159PT) had increased levels of pStat3 (Figure 3a) . Interestingly, examining the total Stat3 levels in these cells revealed that the non-tumorigenic breast epithelial cells, MCF-10A and MCF-12A, had substantially lower levels of total Stat3 compared with the breast cancer cell lines. Irrespective of their differential levels of constitutive pStat3, all the cancer lines had from 10 to 25 times the level of total Stat3 compared with these cells. Importantly, two pStat3-low cell lines, T47D and ZR-75-1, had some of the highest levels of total Stat3. We examined six pStat3-low cell lines MCF-7, T47D, ZR-75-1, MDA-MB-453, MCF-10A and MCF-12A-along with three pStat3-high cell lines MDA-MB-231, MDA-MB-468 and Sum159PT-for PL sensitivity in anchorageindependent growth assays, which clearly revealed ( Table 2 ) that all the pStat3-high cells were effectively inhibited within 16 h with IC 50 s ranged from 2.8 to 12.9 μM. In contrast, the pStat3-low cells, for example, the MCF-10A, MCF-12A, MDA-MB-453, ZR-75-1 and T47D had higher IC 50 s (ranging from 15.5 to 100 μM). Importantly, however, the results of incubation of cell lines with PL for a longer time period (80 h) revealed that there is a significant negative correlation between PL IC 50 values and the total Stat3 levels in these cell lines (Pearson r = À 0.7739, P = 0.0144), indicating that with longer incubation, PL sensitivity correlates to levels of total or U-Stat3. Thus, it appears that PL not only is able to reduce levels of constitutive and ligand-induced pStat3 within breast cancer cells, it also is able to target U-Stat3; the mechanism for PL targeting of U-Stat3 is an area of active investigation in our laboratory.
PL was shown previously to induce apoptosis of leukemia cell lines 45 but its mechanism of action was not explored. More recently, PL was identified in a high-throughput screen designed to identify compounds that activate p53. 40 Detailed analysis demonstrated that PL selectively induced apoptosis in various cancer cells, including breast cancer, by decreasing their defense against reactive oxygen species (ROS). 40 PL was shown to bind to glutathione S-transferase pi 1 (GSTP1) and carbonyl reductase 1 and to inhibit GSTP1 activity; however the IC 50 for GSTP1 inhibition was modest (~100 μM), while the IC 50 for carbonyl reductase 1 not reported. The high IC 50 reported and the inability of overexpression of GSTP1 and carbonyl reductase 1 to fully rescue a PL-susceptible cancer cell from PL-induced apoptosis strongly suggests that apoptosis induction by PL is mediated, at least in part, by affecting other targets. Our findings clearly support Stat3 as another key PL target and that PL induces cancer cell apoptosis through modulating the balance of anti-and proapoptotic proteins within cancer cells by inhibiting Stat3.
Stat3 has previously been demonstrated to be a major regulator of cellular defense against ROS, which raises the distinct possibility that some of the effects of PL on ROS defense reported above 40, 46 may be mediated through Stat3 inhibition. When mice engineered to have tissue-specific Stat3 deletions were subjected to injury models, they displayed increased ROS production and injury within their cardiomyocytes, astrocytes and osteoblast/osteocytes compared with WT mice. [47] [48] [49] [50] [51] In these and other experiments, Stat3 was shown to upregulate expression of superoxide dismutase (MnSOD), 52 the metallothioneins MT1 and MT2 53 and to modulate a variety of other oxidative stress and defense genes. Specifically, MT2, IDH2, OPLAH, PRDX6, SOD3, GPX4, GSR, PRDX5, NFE2L1, MAPK10, BACE2, PRDX5, PARK7 and NDUFS4 were shown to be upregulated by Stat3, 49 whereas GSS, GGTLA1, GPX7, ANPEP, GSTA3, Ptges, NQO1 and Ptgis were downregulated by Stat3. 49 To determine if PL modulated mRNA transcript levels of ROS defense genes through its inhibitory effect on Stat3, we used a commercially obtained panel of quantitative reverse transcriptase-PCR primers for 84 genes involved in ROS metabolism (PAHS 065A, SA Biosciences/Qiagen (Valencia, CA, USA)), which included many genes reported to be Stat3 regulated (Supplementary Table 3 ). Primers for the remaining 13 Stat3-regulated ROS metabolism genes, which were not included in this panel, were synthesized. Levels of mRNA transcript for these 97 (84+13) genes were determined in total RNA isolated from MDA-MB-468 cells incubated without or with PL (30 μM PL for 6-8 h); 77 out of 97 genes had detectable levels for analysis. Out of these 77 genes, 19 genes (25%) were affected by PL treatment at 6 h (⩾20% change, P o0.05) and 34 (44%) were affected at 8 h (⩾20% change, Po 0.05). Out of 14 anti-oxidant genes, previously shown to be upregulated by Stat3 (Supplementary Table 3) , PL treatment for 8 h significantly downregulated 8 genes (MT2A, IDH2, NFE2L1, GSR, BACE2, NDUFS4, PARK7 and FOXM1). Out of the 8 genes, reported to be negatively regulated by Stat3 (Supplementary Table 3 ), 4 genes (NOS2, GSS, NQO1, and GGT5) were upregulated by PL treatment for 8 h. In addition to known Stat3-regulated genes, PL significantly downregulated six additional transcripts encoding proteins with known anti-oxidant properties (MTL5, SCARA3, PXDN, GPX3, RNF7 and SELS; Supplementary Table 7) . These genes could also be additional targets positively regulated by Stat3. In fact, Scara3 appears to be positively regulated by a constitutively active Stat3 mutant (Stat3-C) expression in 3T3 cells. 54 HSP60, a Stat3-regulated gene, 55 positively regulates GPX3 during human adipose tissuederived stem cell differentiation. 56 Thus, apart from PL's role in directly binding to GSTP1, 40 we provide convincing evidence of an additional mechanism of its ROS-modulatory action through its targeting of Stat3 and modulation of the Stat3-mediated anti-oxidant transcriptome. 
MATERIALS AND METHODS

HTFM screening assay
A robust, single-cell, HTFM screening assay was established using GFP-tagged Stat3α, stably expressed (>80% pos) in Stat3 À / À MEF cells 27, 37 and used to measure Stat3 nuclear translocation. The detailed method is provided in Supplementary Figure 1 .
Phosphoflow assay
Kasumi-1 cells, were serum-starved, pre-treated with PL or DMSO and then stimulated with 20 μl of G-CSF (10 ng/ml) for 15 min at 37°C. The assay was stopped by BD Phosflow Stop/Fix Buffer; cells were permeabilized and stained with Alexa647-pStat3. Equal aliquots from each treatment condition were added to a 96-well plate to facilitate the use of the BD HTS (high-throughput sampler) using BD LSR2 (BD, Franklin Lakes, NJ, USA). FCS files were exported and uploaded to Cytobank 57 for determination of phosphoprotein. IC 50 values were calculated using the GraphPad Prism (GraphPad Software, Inc., San Diego, CA, USA).
Ligand-induced Stat3 phosphorylation breast cancer cell lines MCF-7, MDA-MB-453 and T47D cells were serum-starved (1 h), pre-treated with PL or DMSO (2 h) and then stimulated with IL-6/sIL6R treatment (150 ng/ml) for 15 min at 37°C. Whole protein was extracted and pStat3 and GAPDH levels were determined by Luminex/Milliplex (Billerica, MA, USA).
Luminex assay
Total protein was plated in a 96-well filter plate pre-loaded with beads (Millipore, Danvers, MA, USA) coupled to antibody against the indicated analytes. Bead-bound analytes were measured using biotinylated detection antibody specific for a different epitope and streptavidinphycoerythrin. 58, 59 Data were collected and analyzed using the Bio-Plex suspension array system (Luminex 100 system, Bio-Rad Laboratories, Hercules, CA, USA). GAPDH-normalized pStat3 values from each treatment were corrected for untreated cells, expressed as percentage untreated, and used to determine the IC 50 using GraphPad Software, Inc., San Diego, CA, USA.
Surface plasmon resonance assay
Binding of Stat3 (200 nM in 20 mM Tris buffer, pH 8) pre-incubated without or with PL (0.1-1000 μM; 4°for 18 h) to phosphorylated and control nonphosphorylated biotinylated epidermal growth factor receptor-derived dodecapeptides based on sequence surrounding Y1068 60 was measured using a Biacore 3000 biosensor (Biacore Inc., Piscataway, NJ, USA) at 25°C at a flow rate of 10 μl/min for 1-2 min, as described. 61 Analytical methods are provided in Supplementary Information.
Quantitative reverse transcriptase-PCR
Total mRNAs from MDA-MB-468 cells, treated with 30 μM PL for various times, were reverse transcribed and tested for expression of various Stat3-regulated and other relevant genes by real-time PCR using SyBr greenlabeled dNTP mix. The results were expressed as relative mRNA levels normalized to the β-actin mRNA level using the formula [2^[Ct(β-Actin)-Ct (Gene)]. The detailed method is provided in Supplementary Table 1. Oxidative stress and anti-oxidant defense PCR microarray Total mRNAs extracted from MDA-MB-468 cells treated without or with PL, reversed transcribed and used for real-time PCR using the Human Oxidative Stress and Antioxidant Defense RT 2 Profiler PCR microarray according to the manufacturer's protocol (Super-Array Bioscience, Frederick, MD, USA). The detailed method is provided in Supplementary  Information Anchorage-independent cell growth Cells were cultured in triplicates in ultra-low attachment 96-well plates in complete Dulbecco's modified Eagle's medium ± PL for 48-72 h and viable cells were quantitated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. Relative % viability (viability after any treatment÷viability of untreated cells × 100) was plotted along Y axis. At least two replicate experiments were performed and were used for IC 50 calculation using GraphPad software.
Anchorage-dependent cell growth assay Cells were grown in 96-well plates in Dulbecco's modified Eagle's medium with 10% fetal bovine serum ± PL for 24-48 h and viability measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. Optical density was measured at 590 nm using a 96-well multi-scanner (EL-800 universal microplate reader, BioTek Inc., Winooski, VT, USA). Percent viability was determined as before. At least two replicate experiments were performed and used for IC 50 calculation using GraphPad software.
PDX models
With the exception of MC1, 36 patient-derived human breast cancer xenografts were established in our laboratory. 35 The detailed method is provided in Supplementary Information.
MS assay
Excised PDX or GFP + Sum159PT tumors were minced, digested with collagenase, filtered through nylon mesh, suspended in MEGM+ and plated for MSs in 24-well plates in 0.4 ml (20 000/ml) or in 96-well plates in 200 μl (2000/100 μl). Cells were fed twice per week with 0.1 ml (or 50 μl for 96-well plates) of media. After 5-12 days, these were imaged and counted using GelCount at 2400 d.p.i. The percent growth was obtained by (number of colonies÷number of colonies formed by untreated cells × 100). These values were used for IC 50 calculation using the GraphPad software Phosphoprotein antibody array Protein extracted from four pairs of MDA-MB-468 cells-untreated control and PL (30 uM for 2 h) treated-was examined for level of phosphorylation using a antibody array containing well-characterized antibodies against specific 1318 phosphoproteins (http://www.fullmoonbiosystems.com/Products/AntibodyArrays/PEX100.htm) and their unphosphorylated counterparts. Analytical methods are provided in Supplementary Information.
The lentiviral Stat3 reporter system and selection of GFP + Sum159 xenograft-derived cells A lentiviral reporter system for detecting cells with high Stat3 activity was developed in our collaborator's lab (Wei et al., in revision). This included the STAT3-GFP reporter (GFP under the control of four repeats of the M67 sequences, a high-affinity variant of the STAT3-binding sequence from human c-fos promoter), the TATA-GFP-negative control (constructed by deleting the M67 sequences to leave the TATA box only), and an EFS-GFPpositive control (constructed by replacing the four M67 sequences with the elongation factor 1 alpha-binding sequence or EFS). The reporter system proved to be both stringent and sensitive to STAT3 signaling.
Human breast cancer cell line xenograft assay MDA-MB-468 cells were subcutaneously inoculated into right flank of 5-to 6-week-old nude mice (15 mice per group). After~4 weeks, mice were randomized (average tumor size ∼ 100 mm 3 per group) and received either PL (15 mg/kg in 50 μl DMSO) or DMSO (50 μl) intraperitoneally 5 days per week for 3 weeks. Tumor sizes were measured thrice weekly. Subcutaneous tumor volume (mm 3 ) was calculated as 0.5 × (long dimension) × (short dimension) 2 . At the end of 3 weeks, mice were killed. Tumor tissue was excised, weighed and protein extracted for measurement of pStat3, tStat3 and GAPDH by Luminex assay. SUM159PT cells transduced with the Stat3-GFP reporter were injected into the pre-cleared mammary gland of immunocompromised SCID/Beige mouse, the same strain used for PDXs.
